Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients

Haemophilia

Volumn 18, Issue 5, 2012, Pages 794-797

  Pinto, P ^a   Ghosh, K ^a   Shetty, S ^a  

^a NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

Author keywords

Factor VIII; Haemophilia A; India; Inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 8; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; RECOMBINANT BLOOD CLOTTING FACTOR 8; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HAPLOTYPE; HEMOPHILIA A; HUMAN; IMMUNOREGULATION; INDIAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CTLA-4 ANTIGEN; FACTOR VIII; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEMOPHILIA A; HUMANS; INDIA; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-4; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84865536193     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02845.x     Document Type: Article

References (26)

1. Ghosh K, Shetty S, Kulkarni B et al. Development of inhibitors in patients with haemophilia from India. Haemophilia 2001; 7: 273-8.
2. Darby SC, Keeling DM, Spooner RJ et al. UK Haemophilia Centre Doctors' Organisation The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
3. Chang H, Sher GD, Blanchette VS, Teitel JM. The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada. Haemophilia 1999; 5: 247-52.
4. Ghosh K, Jijina F, Shetty S, Madkaikar M, Mohanty D. First-time development of FVIII inhibitor in haemophilia patients during the postoperative period. Haemophilia 2002; 8: 776-80.
5. Ghosh K, Shetty S. Immune Response to FVIII in haemophilia A: an overview of risk factors. Clinic Rev Allergy Immunol 2009; 37: 58-66.
6. Astermark J, Berntorp E, White GC, Kroner BL. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
7. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12(Suppl. 6): 15-22.
8. Astermark J. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors. Haemophilia 2006; 12(Suppl. 6): 8-14.
9. Reding MT, Wu H, Krampf M et al. CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost 1999; 82: 509-15.
10. Reding MT. Immunological aspects of inhibitor development. Haemophilia 2006; 12(Suppl. 6): 30-5.
11. Bidwell J, Keen L, Gallagher G et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999; 1: 3-19.
12. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
13. Astermark J, Oldenburg J, Carlson J et al. MIBS Study Group. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia. Blood 2006; 108: 3739-45.
14. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK, MIBS Study Group. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
15. Chaves AD, Belisário A, Castro G, Santoro M, Rodrigues C. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia. Int J Immunogenet 2010; 37: 79-82.
16. Lozier JN, Rosenberg PS, Goedert JJ, Menashe I. A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A. Haemophilia 2011; 17: 641-9.
17. Bafunno V, Santacroce R, Chetta M et al. Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A. Haemophilia 2010; 16: 469-73.
18. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg HM, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitor. Improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
19. White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
20. Bioque G, Crusius JB, Koutroubakis I et al. Allelic polymorphism in IL-1β and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol 1995; 102: 379-83.
21. Huang D, Pirskanen R, Hjelmstrom P, Lefvert AK. Polymorphisms in IL-1β and IL-1 receptor antagonist genes are associated with myasthenia gravis. J Neuroimmunol 1998; 81: 76-81.
22. Noguchi E, Shibasaki M, Arinami T et al. Association of asthma and the interleukin-4 promoter gene in Japanese. Clin Exp Allergy 1998; 28: 449-53.
23. Deichmann K, Heinzmann A, Bruggenolte E, Forster J, Kuehr J. An MseI RFLP in the human CTLA4 promotor. Biochem Biophys Res Commun 1996; 225: 817-8.
24. Marron MP, Raffel LJ, Garchon HJ et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 1997; 6: 1275-82.
25. Eskdale J, Gallagher G. A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics 1995; 42: 444-5.
26. Myhr KM, Vågnes KS, Marøy TH, Aarseth JH, Nyland HI, Vedeler CA. Interleukin-10 promoter polymorphisms in patients with multiple sclerosis. J Neurol Sci 2002; 202: 93-7.